These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 24291971)

  • 1. [Proposal for rituximab treatment in patients with myasthenia gravis].
    Konno S
    Rinsho Shinkeigaku; 2013; 53(11):1312-4. PubMed ID: 24291971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use and monitoring of low dose rituximab in myasthenia gravis.
    Blum S; Gillis D; Brown H; Boyle R; Henderson R; Heyworth-Smith D; Hogan P; Kubler P; Lander C; Limberg N; Pillans P; Prain K; Staples C; Walsh M; McCombe P; Wong R
    J Neurol Neurosurg Psychiatry; 2011 Jun; 82(6):659-63. PubMed ID: 21071753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action.
    Pescovitz MD
    Am J Transplant; 2006 May; 6(5 Pt 1):859-66. PubMed ID: 16611321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab in myasthenia gravis: a "to be or not to be" inhibitor of T cell function.
    Marino M; Bartoccioni E; Alboini PE; Evoli A
    Ann N Y Acad Sci; 2018 Feb; 1413(1):41-48. PubMed ID: 29369382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis.
    Iorio R; Damato V; Alboini PE; Evoli A
    J Neurol; 2015 May; 262(5):1115-9. PubMed ID: 25308632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A case of refractory generalized myasthenia gravis with anti-acetylcholine receptor antibodies treated with rituximab].
    Hayashi R; Tahara M; Oeda T; Konishi T; Sawada H
    Rinsho Shinkeigaku; 2015; 55(4):227-32. PubMed ID: 25904250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prolonged improvement after rituximab: two cases of resistant muscle-specific receptor tyrosine kinase + myasthenia gravis.
    Burusnukul P; Brennan TD; Cupler EJ
    J Clin Neuromuscul Dis; 2010 Dec; 12(2):85-7. PubMed ID: 21386776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of different dosages of rituximab for refractory generalized AChR myasthenia gravis: A meta-analysis.
    Li T; Zhang GQ; Li Y; Dong SA; Wang N; Yi M; Qi Y; Zhai H; Yang L; Shi FD; Yang CS
    J Clin Neurosci; 2021 Mar; 85():6-12. PubMed ID: 33581791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab for severe myasthenia gravis--experience from five patients.
    Lindberg C; Bokarewa M
    Acta Neurol Scand; 2010 Oct; 122(4):225-8. PubMed ID: 20199513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Rituximab in treatment for neuroimmunological diseases].
    Schröder A; Ellrichmann G; Chehab G; Schneider M; Linker RA; Gold R
    Nervenarzt; 2009 Feb; 80(2):155-6, 158-60, 162-5. PubMed ID: 19183926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of Graves' disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study.
    Salvi M; Vannucchi G; Campi I; Currò N; Dazzi D; Simonetta S; Bonara P; Rossi S; Sina C; Guastella C; Ratiglia R; Beck-Peccoz P
    Eur J Endocrinol; 2007 Jan; 156(1):33-40. PubMed ID: 17218723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab for myasthenia gravis: three case reports and review of the literature.
    Stieglbauer K; Topakian R; Schäffer V; Aichner FT
    J Neurol Sci; 2009 May; 280(1-2):120-2. PubMed ID: 19272616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prolonged B-cell depletion in MuSK myasthenia gravis following rituximab treatment.
    Yi JS; Decroos EC; Sanders DB; Weinhold KJ; Guptill JT
    Muscle Nerve; 2013 Dec; 48(6):992-3. PubMed ID: 24006142
    [No Abstract]   [Full Text] [Related]  

  • 14. 10-year-outcomes after rituximab for myasthenia gravis: Efficacy, safety, costs of inhospital care, and impact on childbearing potential.
    Stieglbauer K; Pichler R; Topakian R
    J Neurol Sci; 2017 Apr; 375():241-244. PubMed ID: 28320139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Memory B cell resurgence requires repeated rituximab in myasthenia gravis.
    Muto K; Matsui N; Unai Y; Sakai W; Haji S; Udaka K; Miki H; Furukawa T; Abe M; Kaji R
    Neuromuscul Disord; 2017 Oct; 27(10):918-922. PubMed ID: 28694074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab for minimal-change nephrotic syndrome in adulthood: predictive factors for response, long-term outcomes and tolerance.
    Guitard J; Hebral AL; Fakhouri F; Joly D; Daugas E; Rivalan J; Guigonis V; Ducret F; Presne C; Pirson Y; Hourmant M; Glachant JC; Vendrely B; Moranne O; Faguer S; Chauveau D
    Nephrol Dial Transplant; 2014 Nov; 29(11):2084-91. PubMed ID: 24920841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of Rituximab in Refractory Generalized anti-AChR Myasthenia Gravis.
    Landon-Cardinal O; Friedman D; Guiguet M; Laforêt P; Heming N; Salort-Campana E; Jouen F; Allenbach Y; Boyer O; Chatenoud L; Eymard B; Sharshar T; Benveniste O
    J Neuromuscul Dis; 2018; 5(2):241-249. PubMed ID: 29865089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab treatment of myasthenia gravis: A systematic review.
    Tandan R; Hehir MK; Waheed W; Howard DB
    Muscle Nerve; 2017 Aug; 56(2):185-196. PubMed ID: 28164324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The role of rituximab in the treatment of ANCA-associated systemic vasculitis].
    Roccatello D; Vangelista A; Pani A
    G Ital Nefrol; 2011; 28(5):474-88. PubMed ID: 22028261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab for the treatment of thymoma-associated and de novo myasthenia gravis: 3 cases and review.
    Nelson RP; Pascuzzi RM; Kessler K; Walsh LE; Faught PP; Ramanuja S; Pescovitz MD; Loehrer PJ
    J Clin Neuromuscul Dis; 2009 Jun; 10(4):170-7. PubMed ID: 19494727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.